Literature DB >> 8666317

Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C.

P H McGuinness1, G A Bishop, D M Painter, R Chan, G W McCaughan.   

Abstract

The balance between a direct cytopathic effect by hepatitis C virus (HCV) and immune-mediated injury remains unclear. This report aims to test the following hypotheses: (1) that intrahepatic HCV load would correlate with the degree of liver injury; (2) that interferon alfa (IFN-alpha) would decrease intrahepatic HCV-RNA levels. Liver tissues (n = 56) were obtained from 47 patients with chronic HCV (9 before and after IFN-alpha therapy). Total RNA was isolated and quantitated for specific HCV RNA by dot-blot polymerase chain reaction (DB-PCR) using a standard curve created from synthetic HCV RNA of known titer to calculate actual RNA levels. A multivariate analysis was undertaken to determine the relationship of intrahepatic HCV-RNA levels with risk factors, length of HCV exposure, and histological injury scores. The confounding effect of HCV genotype was examined by direct sequencing of the NS5b region. Liver HCV RNA ranged from 10(2) to 3.1 x 10(7) molecules per microgram total liver RNA. The multiple regression analysis showed no effect of length of HCV exposure, risk factors, degree of bile duct damage, steatosis, or total Scheuer or Knodell score on RNA levels. No significant confounding effect of HCV genotype on the degree of liver injury was observed. However, genotype 1b had a significantly higher mean intrahepatic HCV-RNA load compared with the other genotypes detected. In the 9 patients who received IFN-alpha, treatment, 7 had no detectable HCV after treatment. This was associated with a significant decrease in intrahepatic HCV-RNA levels (7.57 +/- 2.53 X 10(5) to 1.82 +/- 1.80 x 10(3) molecules per microgram total liver RNA +/- SEM, n = 9, P = .0005). These results do not directly support our hypothesis that increased intrahepatic HCV load is associated with more severe liver injury. Intrahepatic viral load appears to be significantly increased in patients with genotype lb. IFN-alpha treatment does significantly lower intrahepatic HCV load.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666317     DOI: 10.1002/hep.510230404

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  Localization of HCV RNA and capsid protein in human hepatocellular carcinoma.

Authors:  Yi-Ming Dai; Zhi-Ping Shou; Can-Rong Ni; Neng-Jin Wang; Song-Ping Zhang
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

2.  Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage.

Authors:  E Giannini; F Botta; A Fasoli; P Romagnoli; L Mastracci; P Ceppa; I Comino; A Pasini; D Risso; R Testa
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

3.  Transfection of HepG2 cells with infectious hepatitis C virus genome.

Authors:  S Dash; A B Halim; H Tsuji; N Hiramatsu; M A Gerber
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

Review 4.  Steatosis in chronic hepatitis C: why does it really matter?

Authors:  T Asselah; L Rubbia-Brandt; P Marcellin; F Negro
Journal:  Gut       Date:  2006-01       Impact factor: 23.059

Review 5.  Histopathology and detection of hepatitis C virus in liver.

Authors:  P J Scheuer; K Krawczynski; A P Dhillon
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Quantification of hepatitis C virus in human liver and serum samples by using LightCycler reverse transcriptase PCR.

Authors:  Peter A White; Yong Pan; Anthony J Freeman; George Marinos; Rosemary A Ffrench; Andrew R Lloyd; William D Rawlinson
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

7.  Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection.

Authors:  P H McGuinness; D Painter; S Davies; G W McCaughan
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

Review 8.  Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.

Authors:  Daniel J Smith; Joan Combellick; Ashly E Jordan; Holly Hagan
Journal:  Int J Drug Policy       Date:  2015-07-26

9.  Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients.

Authors:  Nadia Bouzgarrou; Elham Hassen; Olfa Bahri; Sallouha Gabbouj; Nabil Ben Mami; Henda Triki; Lotfi Chouchane
Journal:  Hepatol Int       Date:  2011-02-08       Impact factor: 6.047

10.  Quantification of hepatitis C virus (HCV) in liver specimens and sera from patients with human immunodeficiency virus coinfection by using the Versant HCV RNA 3.0 (branched DNA-based) DNA assay.

Authors:  Rosamaria Tedeschi; Eliana Pivetta; Stefania Zanussi; Ettore Bidoli; Mirna Ros; Giampiero di Gennaro; Guglielmo Nasti; Paolo De Paoli
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.